UA87142C2 - 4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide - Google Patents

4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide

Info

Publication number: UA87142C2
Authority: UA; Ukraine
Prior art keywords: disease; benzothiazol; morpholin; piperidine; methoxy
Prior art date: 2004-05-24

Application number

UAA200613530A

Other languages

English (en)

Inventor

Александер Флор

Жан-Люк Моро

Соня Мария Поли

Клаус Ример

Люсинда Стюард

Original Assignee

Ф.Хоффманн-Ля Рош Аг

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-05-24

Filing date

2005-05-17

Publication date

2009-06-25

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34967309&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA87142(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-05-17 Application filed by Ф.Хоффманн-Ля Рош Аг filed Critical Ф.Хоффманн-Ля Рош Аг

2009-06-25 Publication of UA87142C2 publication Critical patent/UA87142C2/ru

Links

XNBRWUQWSKXMPW-UHFFFAOYSA-N Tozadenant Chemical compound C1=2SC(NC(=O)N3CCC(C)(O)CC3)=NC=2C(OC)=CC=C1N1CCOCC1 XNBRWUQWSKXMPW-UHFFFAOYSA-N 0.000 title abstract 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 3
208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 2
208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract 2
208000015802 attention deficit-hyperactivity disease Diseases 0.000 abstract 2
ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 2
208000011117 substance-related disease Diseases 0.000 abstract 2
SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 abstract 1
208000024827 Alzheimer disease Diseases 0.000 abstract 1
208000019901 Anxiety disease Diseases 0.000 abstract 1
206010010904 Convulsion Diseases 0.000 abstract 1
208000023105 Huntington disease Diseases 0.000 abstract 1
206010021143 Hypoxia Diseases 0.000 abstract 1
208000002193 Pain Diseases 0.000 abstract 1
208000018737 Parkinson disease Diseases 0.000 abstract 1
239000002253 acid Substances 0.000 abstract 1
208000026935 allergic disease Diseases 0.000 abstract 1
230000003556 anti-epileptic effect Effects 0.000 abstract 1
239000001961 anticonvulsive agent Substances 0.000 abstract 1
229960003965 antiepileptics Drugs 0.000 abstract 1
239000000164 antipsychotic agent Substances 0.000 abstract 1
229940005529 antipsychotics Drugs 0.000 abstract 1
230000036506 anxiety Effects 0.000 abstract 1
208000006673 asthma Diseases 0.000 abstract 1
229930003827 cannabinoid Natural products 0.000 abstract 1
239000003557 cannabinoid Substances 0.000 abstract 1
229940065144 cannabinoids Drugs 0.000 abstract 1
229940045200 cardioprotective agent Drugs 0.000 abstract 1
239000012659 cardioprotective agent Substances 0.000 abstract 1
229960003920 cocaine Drugs 0.000 abstract 1
230000006735 deficit Effects 0.000 abstract 1
206010013663 drug dependence Diseases 0.000 abstract 1
229960004756 ethanol Drugs 0.000 abstract 1
230000007954 hypoxia Effects 0.000 abstract 1
208000028867 ischemia Diseases 0.000 abstract 1
229940035363 muscle relaxants Drugs 0.000 abstract 1
239000003158 myorelaxant agent Substances 0.000 abstract 1
230000004112 neuroprotection Effects 0.000 abstract 1
229960002715 nicotine Drugs 0.000 abstract 1
SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 abstract 1
229940005483 opioid analgesics Drugs 0.000 abstract 1
-1 opioids Chemical compound 0.000 abstract 1
230000036407 pain Effects 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
230000029058 respiratory gaseous exchange Effects 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
201000000980 schizophrenia Diseases 0.000 abstract 1
201000009032 substance abuse Diseases 0.000 abstract 1
231100000736 substance abuse Toxicity 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Addiction (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Pulmonology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Psychology (AREA)
Immunology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Hydrogenated Pyridines (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

UAA200613530A 2004-05-24 2005-05-17 4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide UA87142C2 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP04102262		2004-05-24

Publications (1)

Publication Number	Publication Date
UA87142C2 true UA87142C2 (en)	2009-06-25

Family

ID=34967309

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UAA200613530A UA87142C2 (en)	2004-05-24	2005-05-17	4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide

Country Status (38)

Country	Link
US (1)	US7368446B2 (ru)
EP (1)	EP1753760B1 (ru)
JP (1)	JP4668265B2 (ru)
CN (1)	CN1956983B (ru)
AR (1)	AR048973A1 (ru)
AT (1)	ATE382619T1 (ru)
AU (1)	AU2005247567B2 (ru)
BR (1)	BRPI0511543B1 (ru)
CA (1)	CA2567703C (ru)
CR (1)	CR8703A (ru)
CY (1)	CY1108104T1 (ru)
DE (1)	DE602005004142T2 (ru)
DK (1)	DK1753760T3 (ru)
DO (1)	DOP2005000091A (ru)
EA (1)	EA011279B1 (ru)
EC (1)	ECSP067018A (ru)
ES (1)	ES2297710T3 (ru)
GT (1)	GT200500124A (ru)
HN (1)	HN2005000238A (ru)
HR (1)	HRP20080027T3 (ru)
IL (1)	IL179364A (ru)
MA (1)	MA28601B1 (ru)
MX (1)	MXPA06013417A (ru)
MY (1)	MY140011A (ru)
NO (1)	NO336939B1 (ru)
NZ (1)	NZ550763A (ru)
PA (1)	PA8633901A1 (ru)
PE (1)	PE20060274A1 (ru)
PL (1)	PL1753760T3 (ru)
PT (1)	PT1753760E (ru)
RS (1)	RS50574B (ru)
SI (1)	SI1753760T1 (ru)
SV (1)	SV2006002125A (ru)
TN (1)	TNSN06371A1 (ru)
TW (1)	TWI358297B (ru)
UA (1)	UA87142C2 (ru)
WO (1)	WO2005116026A1 (ru)
ZA (1)	ZA200609136B (ru)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE521512C2 (sv) *	2001-06-25	2003-11-11	Niconovum Ab	Anordning för administrering av en substans till främre delen av en individs munhåla
DK1803443T3 (en) *	2002-12-20	2019-02-25	Niconovum Ab	Nicotine-containing particulate material with a crystalline cellulose
CA2646942C (en)	2006-03-16	2014-07-29	Modoral Brands Inc.	Improved snuff composition
EP2182803A4 (en) *	2007-07-23	2010-09-01	Synosia Therapeutics	(4-METHOXY-7-MORPHOLIN-4-YL-BENZOTHIAZOL-2-YL) -AMIDE 4-HYDROXY-4-METHYL-PIPERIDINE-1-CARBOXYLIC ACID FOR TREATING POST-TRAUMATIC STRESS DISORDER
HUE025013T2 (hu)	2009-01-12	2016-04-28	Pfizer Ltd	Szulfonamid-származékok
US8168785B2 (en) *	2009-06-17	2012-05-01	Biotie Therapies, Inc.	Benzothiazole derivatives
WO2011101861A1 (en)	2010-01-29	2011-08-25	Msn Laboratories Limited	Process for preparation of dpp-iv inhibitors
JP5872552B2 (ja)	2010-07-09	2016-03-01	ファイザー・リミテッドＰｆｉｚｅｒＬｉｍｉｔｅｄ	化学化合物
WO2012060844A1 (en) *	2010-11-05	2012-05-10	Biotie Therapies, Inc	A2a antagonists as cognition and motor function enhancers
ES2627541T3 (es) *	2012-04-20	2017-07-28	Ucb Pharma, S.A.	Métodos para tratar la enfermedad de Parkinson
CA2988918A1 (en)	2015-06-19	2016-12-22	Biotie Therapies, Inc.	Controlled-release tozadenant formulations
WO2018059531A1 (zh) *	2016-09-30	2018-04-05	苏州晶云药物科技有限公司	一种腺苷a2a受体拮抗剂药物的晶型及其制备方法和用途
JP7287951B2 (ja) *	2017-08-21	2023-06-06	メルクパテントゲゼルシャフトミットベシュレンクテルハフツング	アデノシン受容体アンタゴニストとしてのキノキサリン誘導体
CN110997662B (zh) *	2017-08-21	2023-10-31	默克专利股份公司	作为腺苷受体拮抗剂的苯并咪唑衍生物
WO2019141096A1 (zh) *	2018-01-19	2019-07-25	四川科伦博泰生物医药股份有限公司	取代脲类化合物及其制备方法和用途
US20220088024A1 (en)	2018-12-20	2022-03-24	Biotie Therapies, Inc.	Methods for treating cancer using tozadenant
DE102019110904B4 (de)	2019-04-26	2022-01-20	Helmholtz-Zentrum Dresden - Rossendorf E. V.	N-(4-methoxy-7-morpholinobenzo[d]thiazol-2-yl)-acetamid-Derivate und deren Verwendung
CN116407539B (zh) *	2021-12-30	2025-01-10	上海现代药物制剂工程研究中心有限公司	依匹哌唑甲基脂肪酸酯的用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH505543A (de)	1968-11-01	1971-04-15	Ciba Geigy Ag	Schädlingsbekämpfungsmittel
NL7109150A (ru)	1970-07-06	1972-01-10
US4028374A (en) *	1975-11-03	1977-06-07	Morton-Norwich Products, Inc.	Antibacterial thiocyanatobenzothiazoles
DE2656468A1 (de)	1976-12-14	1978-06-15	Boehringer Mannheim Gmbh	N-(benzthiazol-2-yl)-oxamidsaeure- derivate und verfahren zu ihrer herstellung
KR930005004B1 (ko)	1985-04-15	1993-06-11	쟈안센 파아마슈우티카 엔. 부이.	치환된 n-[(4-피페리디닐)알킬]이환 축합 옥사졸아민 및 티아졸아민의 제조방법
FI91859C (fi)	1987-06-17	1994-08-25	Eisai Co Ltd	Analogiamenetelmä antiallergisena aineena aktiivisen bentsotiatsolijohdannaisen valmistamiseksi
IL90337A0 (en)	1988-05-24	1989-12-15	Pfizer	Aromatic and heterocyclic carboxamide derivatives as antineoplastic agents
WO1990015801A1 (en)	1989-06-22	1990-12-27	Pfizer Inc.	Substituted sulfonamides and related compounds in the treatment of asthma, arthritis and related diseases
DE59005183D1 (de)	1989-11-10	1994-05-05	Agrolinz Agrarchemikalien	Verfahren zur Herstellung reiner, unsymmetrisch disubstituierter Harnstoffe.
PT604657E (pt)	1992-05-21	2000-04-28	Otsuka Pharma Co Ltd	Derivado de diester fosfonico
FR2753970B1 (fr)	1996-10-01	1998-10-30	Synthelabo	Derives de n-(benzothiazol-2-yl) piperidine-1-ethanamine, leur preparation et leur application en therapeutique
JPH11130761A (ja)	1997-10-24	1999-05-18	Otsuka Pharmaceut Co Ltd	ベンゾチアゾール誘導体
CA2309319A1 (en)	1997-11-10	1999-05-20	Bristol-Myers Squibb Company	Benzothiazole protein tyrosine kinase inhibitors
WO1999037630A1 (en)	1998-01-23	1999-07-29	Versicor, Inc.	Oxazolidinone combinatorial libraries, compositions and methods of preparation
WO2000018767A2 (en)	1998-09-30	2000-04-06	Neurogen Corporation	2-piperazino alkylamino benzoazole derivatives: dopamine receptor subtype specific ligands
UA71587C2 (ru)	1998-11-10	2004-12-15	Шерінг Акцієнгезелльшафт	Translated By PlajАМИДЫ АНТРАНИЛОВОЙ КИСЛОТЫ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ЛЕЧЕБНЫХ СРЕДСТВ
GB9824579D0 (en) *	1998-11-10	1999-01-06	Novartis Ag	Organic compounds
IL133680A0 (en)	1999-09-10	2001-04-30	Can Fite Technologies Ltd	Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
AU2000250030A1 (en)	2000-05-12	2001-11-26	Corning Incorporated	Method for manufacturing an optical fiber preform with a protective coating
NZ522928A (en) *	2000-06-21	2005-05-27	F	Benzothiazole derivatives
US6727247B2 (en) *	2001-12-10	2004-04-27	Hoffman-La Roche Inc.	Substituted benzothiazole amide derivatives
US6713499B2 (en) *	2001-12-12	2004-03-30	Hoffman-La Roche Inc.	7-Amino-benzothiazole derivatives

2005
- 2005-05-17 CN CN200580016875XA patent/CN1956983B/zh not_active Expired - Fee Related
- 2005-05-17 AU AU2005247567A patent/AU2005247567B2/en not_active Expired
- 2005-05-17 PL PL05741185T patent/PL1753760T3/pl unknown
- 2005-05-17 RS RSP-2008/0125A patent/RS50574B/sr unknown
- 2005-05-17 BR BRPI0511543-4A patent/BRPI0511543B1/pt not_active IP Right Cessation
- 2005-05-17 SI SI200530160T patent/SI1753760T1/sl unknown
- 2005-05-17 AT AT05741185T patent/ATE382619T1/de active
- 2005-05-17 MX MXPA06013417A patent/MXPA06013417A/es active IP Right Grant
- 2005-05-17 PT PT05741185T patent/PT1753760E/pt unknown
- 2005-05-17 EP EP05741185A patent/EP1753760B1/en not_active Expired - Lifetime
- 2005-05-17 NZ NZ550763A patent/NZ550763A/en not_active IP Right Cessation
- 2005-05-17 DE DE602005004142T patent/DE602005004142T2/de not_active Expired - Lifetime
- 2005-05-17 HR HR20080027T patent/HRP20080027T3/xx unknown
- 2005-05-17 JP JP2007513750A patent/JP4668265B2/ja not_active Expired - Fee Related
- 2005-05-17 CA CA2567703A patent/CA2567703C/en not_active Expired - Lifetime
- 2005-05-17 DK DK05741185T patent/DK1753760T3/da active
- 2005-05-17 ES ES05741185T patent/ES2297710T3/es not_active Expired - Lifetime
- 2005-05-17 WO PCT/EP2005/005329 patent/WO2005116026A1/en not_active Ceased
- 2005-05-17 UA UAA200613530A patent/UA87142C2/ru unknown
- 2005-05-17 EA EA200602048A patent/EA011279B1/ru not_active IP Right Cessation
- 2005-05-18 US US11/132,019 patent/US7368446B2/en not_active Expired - Lifetime
- 2005-05-20 MY MYPI20052309A patent/MY140011A/en unknown
- 2005-05-20 TW TW094116495A patent/TWI358297B/zh not_active IP Right Cessation
- 2005-05-20 DO DO2005000091A patent/DOP2005000091A/es unknown
- 2005-05-23 GT GT200500124A patent/GT200500124A/es unknown
- 2005-05-23 HN HN2005000238A patent/HN2005000238A/es unknown
- 2005-05-23 AR ARP050102104A patent/AR048973A1/es not_active Application Discontinuation
- 2005-05-23 PE PE2005000569A patent/PE20060274A1/es active IP Right Grant
- 2005-05-23 PA PA20058633901A patent/PA8633901A1/es unknown
- 2005-05-24 SV SV2005002125A patent/SV2006002125A/es unknown
2006
- 2006-10-24 CR CR8703A patent/CR8703A/es unknown
- 2006-11-02 ZA ZA200609136A patent/ZA200609136B/xx unknown
- 2006-11-14 TN TNP2006000371A patent/TNSN06371A1/fr unknown
- 2006-11-16 IL IL179364A patent/IL179364A/en active IP Right Grant
- 2006-11-21 EC EC2006007018A patent/ECSP067018A/es unknown
- 2006-11-22 MA MA29481A patent/MA28601B1/fr unknown
- 2006-12-12 NO NO20065732A patent/NO336939B1/no not_active IP Right Cessation
2008
- 2008-02-28 CY CY20081100232T patent/CY1108104T1/el unknown

Also Published As

Publication number	Publication date
AU2005247567B2 (en)	2010-09-02
PE20060274A1 (es)	2006-04-14
MA28601B1 (fr)	2007-05-02
SV2006002125A (es)	2006-02-15
TNSN06371A1 (fr)	2008-02-22
IL179364A0 (en)	2007-03-08
NO20065732L (no)	2006-12-22
EA011279B1 (ru)	2009-02-27
TWI358297B (en)	2012-02-21
HN2005000238A (es)	2008-07-14
MXPA06013417A (es)	2007-01-23
CR8703A (es)	2007-10-04
JP2008500295A (ja)	2008-01-10
ATE382619T1 (de)	2008-01-15
CN1956983B (zh)	2010-05-26
HRP20080027T3 (hr)	2008-05-31
PT1753760E (pt)	2008-02-12
WO2005116026A1 (en)	2005-12-08
DE602005004142D1 (de)	2008-02-14
HK1105199A1 (en)	2008-02-06
PL1753760T3 (pl)	2008-06-30
SI1753760T1 (sl)	2008-04-30
DK1753760T3 (da)	2008-04-14
US20050261289A1 (en)	2005-11-24
AR048973A1 (es)	2006-06-14
NO336939B1 (no)	2015-11-30
JP4668265B2 (ja)	2011-04-13
NZ550763A (en)	2010-07-30
AU2005247567A1 (en)	2005-12-08
PA8633901A1 (es)	2006-05-16
BRPI0511543A (pt)	2008-01-02
CA2567703A1 (en)	2005-12-08
ES2297710T3 (es)	2008-05-01
ECSP067018A (es)	2006-12-29
DE602005004142T2 (de)	2009-01-02
CY1108104T1 (el)	2014-02-12
EA200602048A1 (ru)	2007-06-29
US7368446B2 (en)	2008-05-06
BRPI0511543B1 (pt)	2022-05-10
CN1956983A (zh)	2007-05-02
IL179364A (en)	2013-01-31
DOP2005000091A (es)	2005-06-29
MY140011A (en)	2009-11-30
RS50574B (sr)	2010-05-07
EP1753760A1 (en)	2007-02-21
CA2567703C (en)	2013-03-05
GT200500124A (es)	2005-12-26
ZA200609136B (en)	2008-07-30
EP1753760B1 (en)	2008-01-02
TW200612937A (en)	2006-05-01

Publication	Publication Date	Title
TW200612937A (en)	2006-05-01	4-hydroxy-4-methyl-piperidine-1-carboxylic acid(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide
JO2286B1 (en)	2005-09-12	Modified compounds of the adenosine receptor group
YU96502A (sh)	2006-01-16	Derivati benzotiazola
MY153979A (en)	2015-04-30	Substituted piperidino-dihydrothienopyrimidine
JP2004534816A5 (ru)	2010-11-18
NO20082264L (no)	2008-07-22	Histamin-3 reseptorantagonister
WO2008002621A3 (en)	2008-02-21	Benzyl-substituted quinolone m1 receptor positive allosteric modulators
MXPA04004683A (es)	2004-08-12	Derivados de benzotiazoles tal como ligandos de receptores de adenosina.
CA2498291A1 (en)	2004-03-25	Diazabicyclic compounds useful in the treatment of cns and other disorders
SG140605A1 (en)	2008-03-28	Benzothiazole derivatives
DE602007010445D1 (de)	2010-12-23	Verfahren zur synthese von (+) und (-)-1-aryl-3-azabicycloä3.1.0ühexanen
EA200801302A1 (ru)	2009-02-27	Композиции и способы лечения нарушений цнс
JO2502B1 (en)	2009-10-05	4-Hydroxy-4-methyl-piperidine-1-carboxylic acid-4) methoxy-7-morpholine-4-yl-benzothiazole-2-yl) -amide
WO2009134668A3 (en)	2009-12-30	4-oxo-1,4-dihydroquinoline m1 receptor positive allosteric modulators
BRPI0816571A2 (pt)	2015-12-22	"composto, processo para preparação do composto, composição farmacêutica, agente e método para o tratamento de uma doença ou uma desordem do sistema nervoso central relacionada à ou afetada pelo recptor 5-ht6"
TW200608970A (en)	2006-03-16	Substituted benzothiazoles
IL194750A0 (en)	2009-08-03	Process for the synthesis of (+)and(-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane
TH98482B (th)	2009-10-08	เกลือซินาโฟเอตของสารประกอบ5-ออกซาโซล-2-อิล-ควิโนลีนที่ถูกแทนที่
IL202282A0 (en)	2010-06-16	Prolinamide-tetrazole derivatives as nk3 receptor antagonists
ATE440826T1 (de)	2009-09-15	Benzoxazolonderivate, verfahren zu deren herstellung und deren anwendungen
CY1114789T1 (el)	2016-12-14	Ανταγωνιστες υποδοχεα ισταμινης-3
GEP20084455B (en)	2008-08-10	Use of formamide derivatives as adrenoceptor
ATE485820T1 (de)	2010-11-15	Verwendung von n-(dibenz (b,f)oxepin-10-ylmethyl)-n-methyl-n-prop-2-inyl min (omigapil) zur prophylaxe und/oder behandlung von muskeldystrophie
HK1170122A1 (zh)	2013-02-22	喹啉酰胺m1受體陽性的别構調節劑